Kailera (KLRA) CTO Nicholson Nur Receives 220,000-Share Award

What Happened
Nicholson Nur, Chief Technology Officer of Kailera Therapeutics (KLRA), received a grant/award of 220,000 derivative shares (reported as acquired at $0.00) on September 7, 2026. The filing lists this as an award/derivative grant rather than an open‑market purchase or sale, so no cash changed hands in this reported transaction.

Key Details

• Transaction date: 2026-09-07; SEC filing date: 2026-09-09 (filed timely).
• Instrument: derivative award (reported as acquisition "A"); 220,000 shares acquired at $0.00.
• Vesting (footnote): 25% vests on August 31, 2027, then the remainder vests in 36 substantially equal monthly installments, subject to continued service.
• Shares owned after transaction: not disclosed in this filing.
• No indication of immediate exercise or sale of shares; this is a standard compensation grant.

Context
This is an executive compensation award that will vest over time and thus does not represent an immediate change in market holdings or a buy/sell signal. Such grants are common for aligning executive incentives with company performance; the vesting schedule requires continued employment before the shares/options become exercisable.